GlobalGov › Spain › Solicitation

Spain – Pharmaceutical products – Suministro de Everolimus (DOE), Riluzol (DOE), Alfa 1 antitripsina (DOE), Trióxido arsénico (DOE), Inhibidor de C1 derivado del plasma (DOE) y complejo protombina humana en sus distintas composiciones

Osakidetza - Servicio Vasco De Salud - Organización Central · Spain government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

$3.4M
Est. Value
Active
Status

Opportunity Overview

L1_EVEROLIMUS (DOE) con indicación para cáncer de mama avanzado con receptor hormonal positivo, para tumores neuroendocrinos de origen pancreático, ga | L5_ALFA1 ANTITRIPSINA (DOE) CON UNA CONCENTRACION DE 50 mg/ml TRAS LA RECONSTITUCION | L6_ALFA1 ANTITRIPSINA (DOE) CON UNA CONCENTRACION DE 25 mg/ml TRAS LA RECONSTITUCION | L7_TRIÓXIDO ARSÉNICO (DOE) 1MG/ML | L8_TRIÓXIDO ARSÉNICO (DOE) 2MG/ML | L9_INHIBIDOR DE C1 DERIVADO DE PLASMA (DOE) ENVASE 2 VIALES DE 500 UI PARA TRATAMIENTO Y PREVENCIÓN PREOPERATORIA DE CRISIS DE ANGIOEDEMA EN ADULTOS, | L12_COMPLEJO DE PROTROMBINA HUMANA con: factores de coagulación II (280760 UI), VII (180480 UI), IX (500 UI), X (360600 UI), proteína C (260620 UI) y

This Spain Health Services opportunity is one most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyOsakidetza - Servicio Vasco De Salud - Organización Central
CountrySpain
CategoryHealth Services
Estimated value$3.4M
PublishedSeptember 24, 2026
Procurement stageRequest for Proposal (RFP)
Response dueNot specified / rolling
StatusOpen — accepting responses
Original languageSpanish — members read it in their own language
Official sourceView original notice
Last verifiedOctober 04, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Spain market overview →Browse all categories →

Related Opportunities in Spain

Spain – Pharmaceutical products – Suministro de Apalutamida(DOE), Paliperidona(DOE),Etravirina(DOE),Daratumumab(DOE),Ibrutinib(DOE),Guselkumab(DOE),Asociación Darunavir/Cobicistat(DOE),Selexipag(DOE),Lazertinib(DOE) Y Amivantamab(DOE)
Spain – Pharmaceutical products – Suministro de la asociación de Pertuzumab (DOE) y Trastuzumab (DOE), Emicizumab (DOE), Faricimab (DOE), Glofitamab (DOE), Obinutuzumab (DOE) y Trastuzumab emtansina (DOE)
Spain – Pharmaceutical products – Suministro de Tafamidis (DOE) y Crizotinib (DOE)
Spain – Pharmaceutical products
Spain – Pharmaceutical products – Suministro de Anakinra (DOE) y Efmoroctocog alfa (DOE)
Spain – Pharmaceutical products – Suministro de Alectinib (DOE), Atezolizumab (DOE), Cobimetinib (DOE), Dornasa alfa (DOE), Pertuzumab (DOE), Polatuzumab vedotina (DOE), Rituximab (DOE) subcutáneo, Vemurafenib (DOE) y Vismodegib (DOE)
Spain – Pharmaceutical products – Contrato de suministro de medicamentos a la OSI Barrualde-Galdakao para dar cobertura a personas con derecho a prestación farmacéutica en las residencias de la Comunidad Autónoma de Euskadi (CAE).
Spain – Heating, ventilation and air-conditioning installation work – Ampliación del sistema de producción y distribución térmica y construcción de la nueva galería de instalaciones en el Hospital Universitario de BasurtoBilbao

See every Spain Health Services opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Spain Health Services intelligence report in your inbox

A personalized report on Spain Health Services opportunities, emailed in 5-10 minutes. One per month, no account needed.